Vertex announces european commission approval of alyftrek®, a new once-daily cftr modulator for the treatment of cystic fibrosis

London--(business wire)--vertex pharmaceuticals (nasdaq: vrtx) today announced that the european commission has granted approval for alyftrek® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (cf) ages 6 years and older who have at least one non-class i mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene. “thousands of people with cf across the eu may now benefit from this new, once-daily medicine, which has demonstrated further.
VRTX Ratings Summary
VRTX Quant Ranking